Oral berotralstat for hereditary angioedema prophylaxis in patients aged 2 to <12 years
Jolanta Bernatoniene(Bristol Royal Hospital for Children), Emel Aygören‐Pürsün, Elsa Phillips‐Anglés(Hospital Universitario La Paz), William Yang(Ottawa Allergy Research Corporation), Anne Pagnier(Centre Hospitalier Universitaire de Grenoble), Heather A. Iocca(BioCryst Pharmaceuticals (United States)), Mauro Cancian(University of Padua), David Hagin(University of Washington), Tamar Kinaciyan(Medical University of Vienna), Noémi‐Anna Bara, Marcin Stobiecki(Jagiellonian University), Daniel Petroni(Allergy, Asthma and Clinical Research Center), Stéphane Gayet(Assistance Publique Hôpitaux de Marseille), Daniel Long(BioCryst Pharmaceuticals (United States)), Michael DeSpirito(BioCryst Pharmaceuticals (United States)), M. Bourgoin‐Heck(Sorbonne Université), Elena Mateescu(BioCryst Pharmaceuticals (United States)), Douglas Johnston
Cited by 5
Related Papers
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy
|JAMA|2019|271
Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy
|JCI Insight|2019|188
Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome
|Frontiers in Immunology|2018|186
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
|Transplantation and Cellular Therapy|2021|164
The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1
|Journal of Clinical Immunology|2015|137